Business Wire

Belkin Announces Mobile Charging Accessories That Are Made-to-Move and New Ways to Protect and Connect Devices

Share

Belkin International at Exhibit Hall 3.2, stand #210

Belkin, a leading consumer electronics brand for over 40 years, today announced 11 new travel-ready products across its mobile charging category, as well as solutions to enable more flexible options to work while on the go. Designed in California at its in-house labs, the new announcements underscore Belkin innovation, quality and its commitment to building products consumers need. All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905171274/en/

Belkin announces new BoostCharge collection at IFA 2024 (Photo: Business Wire)

Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.

Foldable Wireless Chargers with Qi2

BoostCharge Magnetic Foldable Charger

This folding stand design is compact and travel ready. Delivering 15W of fast wireless charging to iPhone and other Qi2 enabled devices, its powerful magnetic connection secures the device to charging stand and magnetically holds it vertically or horizontally for hands-free use. Use the elevated, customizable position to scroll or watch, and support the Standby Mode feature for iPhone users. It is available in two versions: standalone charges phone only; the 2-in-1 version charges phone and earbuds. 20W power supply and USB-C cable are included. Premium materials include soft touch phone pad, non-slip base and durable hinge construction.

Price: $44.99 / £39.99 / €44.99 to $69.99 / £59.99 / €69.99
Availability: Standalone version coming September 2024; 2-in-1 version available now at belkin.com and available from Autumn 2024 in select retailers worldwide.

BoostCharge 3-in-1 Magnetic Foldable Charger

Charge all your essentials with this foldable 3-in-1. Both portable and with customizable charging angles, it delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. If used as a pad, keep it flat. If a stand is preferred, the pad lifts easily and holds steady. Simply fold it down for safe transport when it’s time to pack it away.

Price: $99.99 / £99.99 / €99.99
Availability: Available now at belkin.com and select retailers worldwide.

BoostCharge Pro Magnetic Wireless Travel Pad

A traveller’s best friend. Available in both 2-in-1 and 3-in-1 versions, use it as a pad or fold up into a stand. It delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. Qi2 magnetic technology means the phone is held secure, optimizing energy usage and safeguarding the device's battery life.

Price: $119.00 / £109.00 / €119.00 to $129.99 / £119.99 / €129.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.

High-capacityPower Banks

BoostCharge Power Bank 10K w/ Integrated Cable

This compact 10K power bank makes charging easy. With integrated PD PPS, charge a USB-C smartphone, earbuds or tablet. It provides the option to split the power and charge multiple devices at once. Available in Black, Blue and Pink and White (MEA exclusive).

Price: $39.99 / £24.99 / €29.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.

BoostCharge Pro 3-Port Laptop Power Bank 20K

This 65W power bank is built with a 20K battery capacity; enough to charge a laptop, MacBook or smartphone quickly and safely. Its full colour digital display shows battery status to easily monitor the remaining charge and manage power needs efficiently for all devices. Options for 65W PD via single USB-C connection or split the power across two USB-Cs and a USB-A, to charge 3 devices simultaneously.

Price: $89.99 / £79.99 / €89.99
Availability: Available now at belkin.com and belkin.com/uk, and coming soon to select retailers worldwide.

Cables Made More Responsibly

BoostCharge 2-in-1 USB-C and Lightning Cable

Charge existing and future devices with this 2-in-1 cable. MFi and USB-IF certified and tested to over 30,000 bends and over 10,000 plug-ins, this cable will deliver up to 60W of power to any USB-C or Lightning device. It features a built-in interchangeable Lightning connector for users to easily switch between their charging needs. A handy cable strap keeps things tidy and protects it from tangles. Exterior braiding is made of 100% post-consumer recycled polyester, certified by the Global Recycled Standard (GRS), cable head and internal jacket are made of 50% GRS-certified post-consumer recycled thermoplastic.

This is part of a rolling change to transition all our PVC and Braided PVC to PCR material.

Price: $24.99 / £19.99 / €24.99
Availability: Coming Autumn 2024 to select retailers worldwide.

Portable Keyboards for Work-on-the-go

Pro Keyboard Case collection

The Belkin Pro Keyboard case makes working from anywhere, easy. The backlit Bluetooth keyboard pairs to iPad to offer the ease of use of an external keyboard with the added defence of a protective cover. The premium faux leather exterior protects the device, while a soft, anti-slip interior protects the screen from scratches. It auto wakes/sleeps when opening/closing, and features a large, click-anywhere trackpad. Its long-lasting battery (between 460mAh – 600mAh) holds charge independently from iPad.

  • Everyday Keyboard Case with Cradle for iPad Air 10.9" and iPad Pro 11" £99.99/ €109.99
  • Pro Keyboard Case with Magnetic Stand for iPad Air 10.9" and iPad Pro 11"£139.99 / €149.99
  • Pro Keyboard Case with Magnetic Stand for iPad Pro 12.9"£189.99 / €199.99

Availability: Available now at belkin.com/uk,belkin.com/de and Belkin EMEA retailers.

Media kit is available for download HERE.

About Belkin

Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905171274/en/

Contacts

For Media Inquiries:

For Media Inquiries:


Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com

Comms@belkin.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye